Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The addition of pembrolizumab to chemotherapy as adjuvant …